The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
VEGFA and tumour angiogenesis
Open accessAbstract
In this review we summarize the current understanding of signal transduction downstream of vascular endothelial growth factor A (VEGFA) and its receptor VEGFR 2, and the relationship between these signal transduction pathways and the hallmark responses of VEGFA, angiogenesis and vascular permeability. These physiological responses involve a number of effectors, including extracellular signal‐regulated kinases (ERK s), Src, phosphoinositide 3 kinase (PI 3K)/Akt, focal adhesion kinase (FAK), Rho family GTP ases, endothelial NO and p38 mitogen‐activated protein kinase (MAPK). Several of these factors are involved in the regulation of both angiogenesis and vascular permeability. Tumour angiogenesis primarily relies on VEGFA‐driven responses, which to a large extent result in a dysfunctional vasculature. The reason for this remains unclear, although it appears that certain aspects of the VEGFA‐stimulated angiogenic milieu (high level of microvascular density and permeability) promote tumour expansion. The high degree of redundancy and complexity of VEGFA‐driven tumour angiogenesis may explain why tumours commonly develop resistance to anti‐angiogenic therapy targeting VEGFA signal transduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Cai, J., Wu, L., Qi, X., Shaw, L. C., Calzi, S. L., Caballero, S., Jiang, W. G., Vinores, S. A., Antonetti, D. A., Ahmed, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018076 · Cited by 35
RetractedNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591
Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608
Hanahan, D. (1985) · Nature · doi:10.1038/315115a0 · Cited by 1,281
Endothelial cell–cell junctions: happy together
Dejana, E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1357 · Cited by 1,188
Gavard, J., & Gutkind, J. S. (2006) · Nature Cell Biology · doi:10.1038/ncb1486 · Cited by 1,018
Ridley, A. J. (2011) · Cell · doi:10.1016/j.cell.2011.06.010 · Cited by 956
Nozawa, H., Chiu, C., & Hanahan, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601807103 · Cited by 923
Cited by
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
The role of microenvironment in tumor angiogenesis
Jiang, X., Wang, J., Deng, X., Xiong, F., Zhang, S., Gong, Z., Li, X., Cao, K., Deng, H., He, Y., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01709-5 · Cited by 761
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
Palazon, A., Tyrakis, P. A., Macias, D., Veliça, P., Rundqvist, H., Fitzpatrick, S., Vojnovic, N., Phan, A. T., Loman, N., Hedenfalk, I., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.003 · Cited by 521
“Vascular normalization is usually associated with decreased hypoxia, better perfusion of the tumor, and a shift in cancer cell metabolism, although it is clear that vascular normalization does not always lead to increased tumor growth and can also result in reduced or unaffected growth (Carmeliet and Jain, 2011; Claes…”
BackgroundTargeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1
Lin, B., Song, X., Yang, D., Bai, D., Yao, Y., & Lu, N. (2018) · Gene · doi:10.1016/j.gene.2018.02.026 · Cited by 384
Sex differences in cancer mechanisms
Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 366
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175586 · Cited by 362
Mehta, M., Dhanjal, D. S., Paudel, K. R., Singh, B., Gupta, G., Rajeshkumar, S., Thangavelu, L., Tambuwala, M. M., Bakshi, H. A., Chellappan, D. K., et al. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00698-3 · Cited by 330
Targeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 319
Extracellular regulation of VEGF: Isoforms, proteolysis, and vascular patterning
Vempati, P., Popel, A. S., & Mac Gabhann, F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.11.002 · Cited by 313
Vascular permeability—the essentials
Claesson-Welsh, L. (2015) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2015.1064501 · Cited by 304
Self-citationExosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers
Olejarz, W., Kubiak-Tomaszewska, G., Chrzanowska, A., & Lorenc, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165840 · Cited by 299
Roles of circRNAs in the tumour microenvironment
Zhang, Q., Wang, W., Zhou, Q., Chen, C., Yuan, W., Liu, J., Li, X., & Sun, Z. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1125-9 · Cited by 260
Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
Rigamonti, N., Kadioglu, E., Keklikoglou, I., Wyser Rmili, C., Leow, C. C., & De Palma, M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.059 · Cited by 247
Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis
Kreuger, J., & Phillipson, M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.2 · Cited by 160
Hydrogels to model 3D in vitro microenvironment of tumor vascularization
Song, H.-H. G., Park, K. M., & Gerecht, S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.06.002 · Cited by 153
Wang, J., Man, G. C. W., Chan, T. H., Kwong, J., & Wang, C. C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.09.054 · Cited by 127
VEGFR1 promotes cell migration and proliferation through PLCγ and PI3K pathways
Weddell, J. C., Chen, S., & Imoukhuede, P. I. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0037-9 · Cited by 80
YBX1 as an oncogenic factor in T-cell acute lymphoblastic leukemia
Li, H., Zhang, D., Fu, Q., Wang, S., Wang, Z., Zhang, X., Chen, X., Zhu, X., An, N., Chen, Y., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009648 · Cited by 21
Metadata
- Authors
- Claesson‐Welsh, L., & Welsh, M.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2013-01-19
- Volume
- 273
- Issue
- 2
- Pages
- 114-127
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2143926802
- Cited by
- 868
- References
- 124
- FWCI
- 19.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.